Clinical Trial Update: Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma [Phase 1]

View source ↗

Summary

Phase 1 study of intra-pleural GL-ONC1, a genetically modified vaccinia virus, in patients with malignant pleural effusion including mesothelioma and metastatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Malignant Mesothelioma

Drugs mentioned

• GL-ONC1

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lung Cancer | Phase 1 | Status: COMPLETED